scholarly journals Quality of life evaluation of patients after radical treatment of prostate cancer

Author(s):  
S. O. Goldytski ◽  
P. D. Demeshko ◽  
S. A. Krasny

The article provides an overview of the current data on the quality of life in cancer patients, as well as the functional results of radical treatment of prostate cancer. The main goal was to evaluate the functional results in patients after radical prostatectomy, combined radiation therapy, and high dose-rate brachytherapy in 8 to 12 months after treatment. The study included 148 patients treated from 2017 to 2018. The life quality was assessed by specialized questionnaire. The obtained results indicate the better functional results and a higher level of the quality of life of patients after radiation therapy, compared with radical prostatectomy.

2005 ◽  
Vol 96 (1) ◽  
pp. 43-47 ◽  
Author(s):  
Yoshimasa Jo ◽  
Hiratsuka Junichi ◽  
Fujii Tomohiro ◽  
Imajo Yoshinari ◽  
Fujisawa Masato

2015 ◽  
Vol 41 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Jessika A. Contreras ◽  
Richard B. Wilder ◽  
Eric A. Mellon ◽  
Tobin J. Strom ◽  
Daniel C. Fernandez ◽  
...  

2015 ◽  
Vol 117 (2) ◽  
pp. 252-257 ◽  
Author(s):  
Shafak Aluwini ◽  
Wendy M.H. Busser ◽  
Wendimagegn Ghidey Alemayehu ◽  
Joost L. Boormans ◽  
Wim J. Kirkels ◽  
...  

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 278-278
Author(s):  
Jessika Contreras ◽  
Richard Wilder ◽  
Eric Albert Mellon ◽  
Tobin Joel Crill Strom ◽  
Daniel Celestino Fernandez ◽  
...  

278 Background: There is little information in the literature on health-related quality-of-life (HRQOL) changes due to high-dose-rate (HDR) brachytherapy monotherapy for prostate cancer. Methods: We conducted a prospective study of HRQOL changes due to HDR brachytherapy monotherapy for low risk or favorable intermediate risk prostate cancer. Forty-nine of 84 (58%) patients who were treated between February 2011 and April 2013 completed 50 questions comprising the Expanded Prostate Cancer Index Composite (EPIC) before treatment and 6 and/or 12 months after treatment. Results: Six months after treatment, there was a significant decrease (p<0.05) in EPIC urinary, bowel, and sexual scores, including urinary overall, urinary function, urinary bother, urinary irritative, bowel overall, bowel bother, sexual overall, and sexual bother scores. By one year after treatment, all EPIC scores had increased and were not significantly different from baseline values. Conclusions: HDR brachytherapy monotherapy is well-tolerated in patients with low and favorable intermediate risk prostate cancer. Urinary, bowel, and sexual domain scores returned to close to baseline 12 months after treatment.


Sign in / Sign up

Export Citation Format

Share Document